{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:08:37Z","timestamp":1790366917893,"version":"4.1.0"},"reference-count":63,"publisher":"Japan Neurosurgical Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2014]]},"DOI":"10.2176\/nmc.ra.2014-0178","type":"journal-article","created":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T23:09:03Z","timestamp":1417216143000},"page":"966-973","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of Pituitary Carcinomas and Atypical Pituitary Adenomas: A Review"],"prefix":"10.2176","volume":"54","author":[{"given":"Toshio","family":"HIROHATA","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Teikyo University"},{"name":"Department of Neurosurgery, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudo","family":"ISHII","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Teikyo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"MATSUNO","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Teikyo University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","unstructured":"1) Lloyd RV, Kovacs K, Young WF Jr, Farrel WE, Asa SL, Truillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E, DeLellis RA, Heitz PU: Pituitary tumors, <i>in<\/i> DeLellis R, Lloyd RV, Heitz PV, Eng C (<i>eds<\/i>): <i>Introduction. WHO Classification of Tumors of the Endocrine Organs: Pathology and Genetics of Endocrine Organs<\/i>. Lyon, IARC Press, 2004, pp 10\u201313"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. <i>Neurosurgery<\/i> 38: 9\u2013106; discussion 106\u2013107, 1996","DOI":"10.1097\/00006123-199601000-00024"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Scheithauer BW, Kovacs KT, Laws ER, Randall RV: Pathology of invasive pituitary tumors with special reference to functional classification. <i>J Neurosurg<\/i> 65: 733\u2013744, 1986","DOI":"10.3171\/jns.1986.65.6.0733"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Saeger W, L\u00fcdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S: Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. <i>Eur J Endocrinol<\/i> 156: 203\u2013216, 2007","DOI":"10.1530\/eje.1.02326"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER: Atypical pituitary adenomas: incidence, clinical characteristics, and implications. <i>J Neurosurg<\/i> 114: 336\u2013344, 2011","DOI":"10.3171\/2010.8.JNS10290"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF, Lloyd RV, Davis DH, Guthrie BL, Schoene WC: Pituitary carcinoma: a clinicopathologic study of 15 cases. <i>Cancer<\/i> 79: 804\u2013812, 1997","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3"},{"key":"7","unstructured":"7) Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF, Lloyd RV: Pituitary carcinoma: a clinicopathological review. <i>Neurosurgery<\/i> 56: 1066\u20131074; discussion 1066\u20131074, 2005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ragel BT, Couldwell WT: Pituitary carcinoma: a review of the literature. <i>Neurosurg Focus<\/i> 16: E7, 2004","DOI":"10.3171\/foc.2004.16.4.8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB: Clinical review: Diagnosis and management of pituitary carcinomas. <i>J Clin Endocrinol Metab<\/i> 90: 3089\u20133099, 2005","DOI":"10.1210\/jc.2004-2231"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A: DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. <i>J Clin Endocrinol Metab<\/i> 98: 1130\u20131136, 2013","DOI":"10.1210\/jc.2012-2924"},{"key":"11","unstructured":"11) Tamiya T: Surgical procedures for giant pituitary tumors, <i>in<\/i> Yamaura A (<i>ed<\/i>): <i>Brain Tumors II<\/i>, <i>Noshinkeigeka Taikei, the 1st edition.<\/i> Tokyo, Nakayama Shoten, 2004, pp 309\u2013323 (Japanese)"},{"key":"12","unstructured":"12) Yamada S, Ohyama K, Fukuhara N: Choice of operative procedures of transsphenoidal surgery: approaches for the combined surgery with craniotomy. <i>Folia Endocrinogica Japonica<\/i> 82(Supple): 37\u201339, 2006 (Japanese)"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kaltsas GA, Grossman AB: Malignant pituitary tumours. <i>Pituitary<\/i> 1: 69\u201381, 1998","DOI":"10.1023\/A:1009975009924"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM: The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. <i>J Clin Endocrinol Metab<\/i> 83: 4233\u20134238, 1998","DOI":"10.1210\/jcem.83.12.5300"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Cartwright DM, Miller TR, Nasr AJ: Fine-needle aspiration biopsy of pituitary carcinoma with cervical lymph node metastases: a report of two cases and review of the literature. <i>Diagn Cytopathol<\/i> 11: 68\u201373, 1994","DOI":"10.1002\/dc.2840110116"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wilson DF: Pituitary carcinoma occurring as middle ear tumor. <i>Otolaryngol Head Neck Surg<\/i> 90: 665\u2013666, 1982","DOI":"10.1177\/019459988209000530"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Garr\u00e3o AF, Sobrinho LG, Pedro-Oliveira, Bugalho MJ, Boavida JM, Raposo JF, Loureiro M, Limbert E, Costa I, Antunes JL: ACTH-producing carcinoma of the pituitary with haematogenic metastases. <i>Eur J Endocrinol<\/i> 137: 176\u2013180, 1997","DOI":"10.1530\/eje.0.1370176"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Swords FM, Allan CA, Plowman PN, Sibtain A, Evanson J, Chew SL, Grossman AB, Besser GM, Monson JP: Stereotactic radiosurgery XVI: a treatment for previously irradiated pituitary adenomas. <i>J Clin Endocrinol Metab<\/i> 88: 5334\u20135340, 2003","DOI":"10.1210\/jc.2002-020356"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, Horvath E, Kovacs K, Kuroki T, Young WF Jr, Sebo TJ, Riehle DL, Belzberg AJ: Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases<i>. J Neurosurg<\/i> 96(2): 352\u2013360, 2002","DOI":"10.3171\/jns.2002.96.2.0352"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Walker JD, Grossman A, Anderson JV, Ur E, Trainer PJ, Benn J, Lowy C, S\u00f6nksen PH, Plowman PN, Lowe DG: Malignant prolactinoma with extracranial metastases: a report of three cases. <i>Clin Endocrinol (Oxf)<\/i> 38: 411\u2013419, 1993","DOI":"10.1111\/j.1365-2265.1993.tb00523.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kaltsas GA, Besser GM, Grossman AB: The diagnosis and medical management of advanced neuroendocrine tumors. <i>Endocr Rev<\/i> 25: 458\u2013511, 2004","DOI":"10.1210\/er.2003-0014"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. <i>N Engl J Med<\/i> 352: 997\u20131003, 2005","DOI":"10.1056\/NEJMoa043331"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lim S, Shahinian H, Maya MM, Yong W, Heaney AP: Temozolomide: a novel treatment for pituitary carcinoma. <i>Lancet Oncol<\/i> 7: 518\u2013520, 2006","DOI":"10.1016\/S1470-2045(06)70728-8"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. <i>Clin Endocrinol (Oxf)<\/i> 65: 552\u2013553, 2006","DOI":"10.1111\/j.1365-2265.2006.02653.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. <i>Hum Pathol<\/i> 38: 185\u2013189, 2007","DOI":"10.1016\/j.humpath.2006.07.014"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE: Long-term response of pituitary carcinoma to temozolomide. Report of two cases. <i>J Neurosurg<\/i> 105: 621\u2013626, 2006","DOI":"10.3171\/jns.2006.105.4.621"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM: Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. <i>Pituitary<\/i> 10: 81\u201386, 2007","DOI":"10.1007\/s11102-007-0014-1"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ: Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. <i>Clin Endocrinol (Oxf)<\/i> 71: 226\u2013233, 2009","DOI":"10.1111\/j.1365-2265.2008.03487.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Guzel A, Tatli M, Senturk S, Guzel E, Cayli SR, Sav A: Pituitary carcinoma presenting with multiple metastases: case report. <i>J Child Neurol<\/i> 23: 1467\u20131471, 2008","DOI":"10.1177\/0883073808319078"},{"key":"30","unstructured":"30) Debono M, Bridgewater C, Ross R, Newell-Price J: Treating an aggressive prolactinoma in a patient with MEN 1: beneficial response totemozolomide. Society for Endocrinology BES. <i>Endocrine Abstracts<\/i> 15: 188, 2008"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD: Use of temozolomide in aggressive pituitary tumors: case report. <i>Neurosurgery<\/i> 64(4): E773\u2013E774; discussion E774, 2009","DOI":"10.1227\/01.NEU.0000339115.12803.4E"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Byrne S, Karapetis C, Vrodos N: A novel use of temozolomide in a patient with malignant prolactinoma. <i>J Clin Neurosci<\/i> 16: 1694\u20131696, 2009","DOI":"10.1016\/j.jocn.2009.05.013"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M: Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. <i>Eur J Endocrinol<\/i> 161: 631\u2013637, 2009","DOI":"10.1530\/EJE-09-0389"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S: High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing\u2019s disease. <i>Eur J Endocrinol<\/i> 161: 553\u2013559, 2009","DOI":"10.1530\/EJE-09-0414"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM: Treatment of Nelson\u2019s syndrome with temozolomide. <i>Eur J Endocrinol<\/i> 160: 115\u2013119, 2009","DOI":"10.1530\/EJE-08-0557"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K: Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. <i>Hormones (Athens)<\/i> 8: 303\u2013306, 2009","DOI":"10.14310\/horm.2002.1247"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL: Temozolomide (Temodar<sup>\u00ae<\/sup>) and capecitabine (Xeloda<sup>\u00ae<\/sup>) treatment of an aggressive corticotroph pituitary tumor. <i>Pituitary<\/i> 14: 418\u2013424, 2011","DOI":"10.1007\/s11102-009-0211-1"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Morin E, Berthelet F, Weisnagel J, Bidlingmaier M, Serri O: Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. <i>Pituitary<\/i> 15: 97\u2013100, 2012","DOI":"10.1007\/s11102-010-0232-9"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thom\u00e9 C: SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. <i>Exp Clin Endocrinol Diabetes<\/i> 118: 760\u2013763, 2010","DOI":"10.1055\/s-0030-1253419"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Dillard TH, Gultekin SH, Delashaw JB, Yedinak CG, Neuwelt EA, Fleseriu M: Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. <i>Pituitary<\/i> 14: 80\u201391, 2011","DOI":"10.1007\/s11102-010-0264-1"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Vance ML, Thorner MO, Laws ER, Lopes MB: Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. <i>J Clin Endocrinol Metab<\/i> 95: E280\u2013E290, 2010","DOI":"10.1210\/jc.2010-0441"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Curt\u00f2 L, Torre ML, Ferra\u00f9 F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannav\u00f2 S: Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing\u2019s disease\u2014report of a case and literature review. <i>Scientific World Journal<\/i> 10: 2132\u20132138, 2010","DOI":"10.1100\/tsw.2010.210"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Fran\u00e7ois P, Jouanneau E, Passagia JG, Bernier M, Corn\u00e9lius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T: Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. <i>J Clin Endocrinol Metab<\/i> 95: 4592\u20134599, 2010","DOI":"10.1210\/jc.2010-0644"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M: Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. <i>Eur J Endocrinol<\/i> 163: 843\u2013851, 2010","DOI":"10.1530\/EJE-10-0629"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A: A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. <i>Neurosurgery<\/i> 68: E1761\u2013E1767; discussion E1767, 2011","DOI":"10.1227\/NEU.0b013e318217161a"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K: Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. <i>Hormones (Athens)<\/i> 10: 162\u2013167, 2011","DOI":"10.14310\/horm.2002.1307"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K: Anti-VEGF therapy in pituitary carcinoma. <i>Pituitary<\/i> 15: 445\u2013449, 2012","DOI":"10.1007\/s11102-011-0346-8"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M: Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. <i>Pituitary<\/i> 15: 276\u2013287, 2012","DOI":"10.1007\/s11102-011-0363-7"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Arnold PM, Ratnasingam D, O\u2019Neil MF, Johnson PL: Pituitary carcinoma recurrent to the lumbar intradural extramedullary space: case report. <i>J Spinal Cord Med<\/i> 35: 118\u2013121, 2012","DOI":"10.1179\/2045772311Y.0000000055"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. <i>Clin Cancer Res<\/i> 13: 2986\u20132991, 2007","DOI":"10.1158\/1078-0432.CCR-06-2053"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E: Treatment of pituitary neoplasms with temozolomide: a review. <i>Cancer<\/i> 117: 454\u2013462, 2011","DOI":"10.1002\/cncr.25413"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T: Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. <i>Clin Endocrinol (Oxf)<\/i> 76: 769\u2013775, 2012","DOI":"10.1111\/j.1365-2265.2012.04381.x"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Matsuno A, Murakami M, Hoya K, Yamada SM, Miyamoto S, Yamada S, Son JH, Nishido H, Ide F, Nagashima H, Sugaya M, Hirohata T, Mizutani A, Okinaga H, Ishii Y, Tahara S, Teramoto A, Osamura RY: Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. <i>Med Mol Morphol<\/i> 47: 1\u20137, 2014","DOI":"10.1007\/s00795-013-0050-z"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Stojic L, Mojas N, Cejka P, Di Pietro M, Ferrari S, Marra G, Jiricny J: Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. <i>Genes Dev<\/i> 18: 1331\u20131344, 2004","DOI":"10.1101\/gad.294404"},{"key":"55","unstructured":"55) Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BKA, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, Keir S, Marcelli S, Bigner DD, Modrich P: Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. <i>Cancer Res<\/i> 57: 2933\u20132936, 1997"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Kinsella TJ: Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. <i>Clin Cancer Res<\/i> 15: 1853\u20131859, 2009","DOI":"10.1158\/1078-0432.CCR-08-1307"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K: Temozolomide in aggressive pituitary adenomas and carcinomas. <i>Clinics (Sao Paulo)<\/i> 67 Suppl 1: 119\u2013123, 2012","DOI":"10.6061\/clinics\/2012(Sup01)20"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M: Activation of RAF\/MEK\/ERK and PI3K\/AKT\/mTOR pathways in pituitary adenomas and their effects on downstream effectors. <i>Endoc Relat Cancer<\/i> 16: 1329\u20131338, 2009","DOI":"10.1677\/ERC-09-0101"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M: The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. <i>Cancer Res<\/i> 70: 666\u2013674, 2010","DOI":"10.1158\/0008-5472.CAN-09-2951"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I: Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. <i>Endocr Relat Cancer<\/i> 16: 1017\u20131027, 2009","DOI":"10.1677\/ERC-08-0269"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J, Raverot G: New targeted therapies in pituitary carcinoma resistant to temozolomide. <i>Pituitary<\/i> 15: 37\u201343, 2012","DOI":"10.1007\/s11102-011-0341-0"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG, Melmed S: Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. <i>Cancer Res<\/i> 68: 6377\u20136386, 2008","DOI":"10.1158\/0008-5472.CAN-08-0508"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S: EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. <i>J Clin Invest<\/i> 121: 4712\u20134721, 2011","DOI":"10.1172\/JCI60417"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/54\/12\/54_ra.2014-0178\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T04:24:27Z","timestamp":1621484667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/54\/12\/54_ra.2014-0178\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2176\/nmc.ra.2014-0178","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"value":"0470-8105","type":"print"},{"value":"1349-8029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}